Sofinnova Partners Founded 1972
Overview
Portfolio analytics
Team
Investments
News & Media
Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 232
Average round size
info
The average size of a deal this fund participated in
$20M
Portfolio companies 140
Rounds per year 2.86
Lead investments 83
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.40
Exits 43
Stages of investment
Early Stage Venture
Late Stage Venture
Seed
Areas of investment
Biotechnology
Electronics
Health Care
Industrial
Software
Summary

Sofinnova Partners appeared to be the VC, which was created in 1972. The company was established in Europe in France. The leading representative office of defined VC is situated in the Paris.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. We can highlight the next thriving fund investment areas, such as Health Care, Medical Device. Among the most popular portfolio startups of the fund, we may highlight Addex Therapeutics, DBV Technologies, MedDay. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

Besides them, we counted 11 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Sofinnova Partners, startups are often financed by Gimv, Idinvest Partners, Bpifrance. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Idinvest Partners, Auriga Partners. In the next rounds fund is usually obtained by Gimv, Andera Partners, Venrock.

This Sofinnova Partners works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2010. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 7-12 deals every year. The average startup value when the investment from Sofinnova Partners is 10-50 millions dollars. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies.

Read more
Notable deals
CompanyIndustryRoundRound SizeDateInvestorsLocation
Mainstay Medical
Biotechnology
Emergency Medicine
Health Care
Medical
Medical Device
Private Equity
108M16 Feb 2021 Ireland, Dublin
Corwave
Health Care
Manufacturing
Medical Device
Late Stage Venture
41M06 Jan 2021 France, Paris
Catamaran Bio
Biopharma
Biotechnology
Early Stage Venture
42M23 Nov 2020 United States, Cambridge
Myricx Pharma
Biotechnology
Life Science
Seed
6M16 Nov 2020 United Kingdom, " United Kingdom"}
GenSight Biologics
Biotechnology
Genetics
Health Care
Medical
Post-IPO Equity
25M22 Oct 2020 France, Paris
Pixium Vision
3D Technology
Health Care
Information Technology
Software
Post-IPO Equity
8M15 Jul 2020 France, Paris
MISSION Therapeutics
Biotechnology
Health Care
Life Science
Therapeutics
Venture - Series Unknown
15M06 Jul 2020 United Kingdom, Cambridge
Protera
AgTech
Biotechnology
Genetics
Health Care
Life Science
Early Stage Venture
5M10 Jun 2020 United States, Sunnyvale
NodThera
Biotechnology
Health Care
Life Science
Early Stage Venture
55M03 Jun 2020 United Kingdom, Uttlesford
News
Protera Announces Final Close of Its $10M Series A Led by Sofinnova Partners
– Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced the final close of its Series A financing, at $10 million. – The round was led by Sofinnova Partners, a leading European life sciences venture capital firm specialized in healthcare and sustainability. – Protera is currently scaling-up its manufacturing process and validating its protein-based ingredients with several multinational companies. – In particular, the fina... Read more
Comet Bio Raises $22M in Series C Funding
– Comet Bio from London, Ontario CA- and Schaumburg, Illinois-based food technology company raised $22M in Series C funding. – The round was led by Open Prairie with participation from Louis Dreyfus Company (LDC), BDC Capital, Sofinnova Partners. – The new investment will be used to meet the market demand for its ingredients. Read more
Review
  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sofinnova Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: